Salarius Pharmaceuticals Announces Two Presentations at the 2022 American Society of Hematology Annual Meeting
03 nov. 2022 09h57 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
27 oct. 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius plans to release additional preclinical results at the American Society of...
Salarius Pharmaceuticals to Present SP-3164 at the 5th Annual Targeted Protein Degradation Conference
19 oct. 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas
18 oct. 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop...
Salarius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
14 oct. 2022 08h43 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of...
Salarius Pharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference
20 sept. 2022 12h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of...
Salarius Pharmaceuticals CEO Issues Letter to Stockholders
13 sept. 2022 08h00 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing medicines for patients fighting cancer and in need of...
Salarius Pharmaceuticals Adds Two Mayo Clinic Sites to its Ongoing Phase 1/2 Trial of Seclidemstat as a Treatment for Ewing’s Sarcoma and FET-Rearranged Sarcomas
22 août 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
Expands Trial to 17 U.S. Sites and 25 Locations Initiation of All Anticipated U.S. Trial Sites Largely Completed HOUSTON, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:...
Salarius Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
08 août 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment...
Salarius Pharmaceuticals Adds Seattle Cancer Care Alliance and Oregon Health & Sciences as Clinical Sites for its Ongoing Trial of Seclidemstat as a Treatment for Ewing Sarcoma and FET-Rearranged Sarcomas
04 août 2022 08h30 HE
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new...